Trial
NCT03131453
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
Amgen; Banner Alzheimer's Institute
Condition
Alzheimers Disease
Intervention
CNP520 50mg
Why stopped
The study was terminated due to safety issues.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-05